Latest Alector News & Updates

See the latest news and media coverage for Alector. We track all announcements, press releases, and industry mentions in real time, all in one place.

Alector

Biopharmaceutical company developing therapies for neurodegenerative diseases

alector.com

Headquarters: South San Francisco, United States
Founded year: 2013
Company type: Public company
Number of employees: 125–200
Industry: Pharmaceuticals

Last updated Today

Latest news about Alector

In short: Alector licensed its Parkinson's therapy AL050 to Genentech for $100M upfront, extending its cash runway into 2029.

Company announcements

October 5 Alector

Alector Licenses AL050 to Genentech for $100 Million Upfront

The deal includes up to $1.17 billion in milestones and royalties, extending Alector's cash runway into 2029.

October 5 Alector

Alector filed an 8-K report on October 5, 2026

This Current Report discloses unscheduled material events or corporate changes occurring after the previous filing date of September 30, 2026.

August 6 Alector

Alector reports second quarter 2026 financial results

The company shared recent portfolio and business updates alongside the quarterly earnings release.

May 7 Alector

Alector reports Q1 2026 results with $206.5M cash and pipeline updates

The company highlights AL037/137 IND submission plans, discontinued nivisnebart trials, and reduced expenses driven by workforce reductions.

Media coverage

Yesterday Yahoo Finance

Roche Stocks: Genentech Commits $100 Million Upfront in Potential $1.27 Billion Parkinson's Deal

Genentech licenses Alector's experimental AL050 program, with another $1.17 billion tied to milestones, plus sales royalties. ...

October 5 Reuters

(ALEC.O) | Stock Price & Latest News | Reuters

Alector soars as Roche licenses Parkinson's therapy for up to $1.27 billion Swiss drugmaker Roche will pay up to $1.27 billion to license Alector's experimental...

April 30 BioSpace

GSK-partnered Alector hit with third neuro failure as Alzheimer’s asset disappoints - BioSpace

Over the last two years, Alector has suffered three setbacks for its neurodegenerative disease pipeline, often forcing the company to downsize.

April 29 Nasdaq

Alector to Discontinue Phase 2 PROGRESS-AD Trial of Nivisnebart (AL101/GSK4527226) in Early Alzheimer's Disease Following Interim Futility Analysis

--Alector remains focused on advancing its pipeline of novel ABC-enabled candidates, including an anti-Aβ antibody for Alzheimer's disease (AD), a GCase enzyme replacement therapy (ERT...

Never miss news about Alector

Track Alector and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Alector competitors & trending companies

Browse news for competitors to Alector and other trending companies.